{"id":65870,"date":"2026-05-21T14:13:34","date_gmt":"2026-05-21T06:13:34","guid":{"rendered":"https:\/\/flcube.com\/?p=65870"},"modified":"2026-05-21T14:13:34","modified_gmt":"2026-05-21T06:13:34","slug":"sino-medical-sciences-secures-eu-label-update-for-ht-supreme-stent-enabling-one-month-dual-antiplatelet-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65870","title":{"rendered":"Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy"},"content":{"rendered":"\n

Sino Medical Sciences Technology Inc.<\/strong> (SHA: 688108<\/a>) announced European Union regulatory approval for a label update<\/strong> to its HT Supreme drug-eluting stent system<\/strong>. The revised labeling now permits dual antiplatelet therapy (DAPT) duration to be reduced to one month<\/strong> following stent implantation in the overall coronary heart disease patient population.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Sino Medical Sciences Technology Inc. (SHA: 688108)<\/td><\/tr>
Product<\/strong><\/td>HT Supreme drug-eluting stent system<\/td><\/tr>
Regulatory Authority<\/strong><\/td>European Union (EU)<\/td><\/tr>
Approval Type<\/strong><\/td>Label update\/indication expansion<\/td><\/tr>
Key Label Change<\/strong><\/td>DAPT duration reduced to one month post-implantation<\/td><\/tr>
Patient Population<\/strong><\/td>Overall coronary heart disease patient population<\/td><\/tr>
Previous Standard<\/strong><\/td>Typically 6-12 months DAPT for drug-eluting stents<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Significance<\/h2>\n\n\n\n